Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol™), a novel isoflav-3-ene, in patients with advanced cancer
- 4 February 2006
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 58 (4) , 427-433
Abstract
Background: We wished to define the maximum tolerated dose (MTD), toxicity, and pharmacokinetics of the novel isoflav-3-ene, NV06 (Phenoxodiol™), a compound with a diphenolic structure related chemically and biologically to genistein and flavopiridol. Patients and Methods: Twenty-one patients with advanced cancers were treated with weekly intravenous administration of NV06 at escalating dose levels with 1–4 patients at each dose cohort. Plasma sampling was undertaken to characterize the pharmacokinetic (PK) profile of the compound. Results: Toxicity was minimal, with asymptomatic Grade 3 lymphocytopenia occurring in nine patients. Nine patients developed Grade 1 nausea, six patients developed Grade 1 increases in alkaline phosphatase, and six patients developed Grade 1 increases in transaminases. Two patients experienced hypersensitivity reactions. The MTD was not reached. Most patients had progressive disease on treatment but eight completed 12 weeks and two completed 24 weeks of treatment. The best response was stable disease of 6 months duration. The plasma half-life (T1/2), clearance (Cl), and volume of distribution (V D) were 304 (±91) min, 82 (±19) ml/min and 32,663 (±7,199) ml, respectively, for total NV06. Conclusions: NV06 is well tolerated and can be given safely as an intravenous infusion over 1–2 h at a dose of at least 30 mg/kg.Keywords
This publication has 15 references indexed in Scilit:
- Phenoxodiol, a Novel Isoflavone, Induces G1 Arrest by Specific Loss in Cyclin-Dependent Kinase 2 Activity by p53-Independent Induction of p21WAF1/CIP1Cancer Research, 2005
- Putting the Rap on AktJournal of Clinical Oncology, 2004
- New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonistsBreast Cancer Research, 2004
- Resistance of Ovarian Carcinoma Cells to Docetaxel Is XIAP Dependent and Reversible by PhenoxodiolOncology Research, 2004
- Phenoxodiol – an isoflavone analog – induces apoptosis in chemoresistant ovarian cancer cellsOncogene, 2003
- Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2003
- Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridolCancer Chemotherapy and Pharmacology, 2002
- Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric CarcinomaJournal of Clinical Oncology, 2001
- Safety of Parenteral Hydroxypropyl β‐CyclodextrinJournal of Pharmaceutical Sciences, 1995
- Hydroxypropylcyclodextrins in Parenteral Use. II: Effects on Transport and Disposition of Lipids in Rabbit and HumansJournal of Pharmaceutical Sciences, 1992